SCHEMBL3793471

SCHEMBL3793471

CCc1ccc(CN2CCOc3ccc(Br)cc32)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.44
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
HDAC1 Q13547 3/20 0.39
HDAC6 Q9UBN7 3/20 0.39
SLC5A1 P13866 1/20 0.38
SLC5A2 P31639 1/20 0.38
AR P10275 1/20 0.36
LMNA P02545 2/20 0.36
MAPT P10636 1/20 0.36
HTT P42858 1/20 0.36
BLM P54132 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
CYP2D6 P10635 1/20 0.36
PIK3CD O00329 3/20 0.36
PIK3CA P42336 3/20 0.36
PIK3CB P42338 3/20 0.36
PIK3CG P48736 3/20 0.36
CCR5 P51681 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1671236 0.86 AR (0.47) KDM4EALDH1A1HDAC1HDAC6AR
SCHEMBL3789909 0.86 SMN1; SMN2 (0.45) KDM4ESMN1; SMN2HDAC1HDAC6LMNA
SCHEMBL31167486 0.83 PTGER3 (0.43) ARLMNAMAPTHTTBLM
SCHEMBL28238549 0.77 HDAC1 (0.56) POLBHDAC1HDAC6ARCYP2D6
SCHEMBL10228321 0.77 PTGER3 (0.43) SMN1; SMN2ARMAPTCYP2D6
SCHEMBL10228536 0.77 CYP2D6 (0.39) SMN1; SMN2HDAC1HDAC6SLC5A1SLC5A2
SCHEMBL3793050 0.76 HTR2A (0.56) POLBKDM4EALDH1A1SMN1; SMN2HDAC1
SCHEMBL1670063 0.75 CYP2D6 (0.40) HDAC1HDAC6SLC5A2ARLMNA
SCHEMBL21941375 0.75 RORC (0.40) AR
SCHEMBL1669951 0.74 AR (0.38) KDM4EALDH1A1SMN1; SMN2HDAC1HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010128152-A1 FUSED HETEROCYCLIC C-GLYCOSIDES FOR THE TREATMENT OF DIABETES NOVARTIS AG (CH) 2010-11-11 WO disclosed